Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$81.20 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)731.37K
Market Cap
$24.04B
Enterprise Value$9.88B
Total Cash (Recent Filing)$14.04B
Total Debt (Recent Filing)$269.60M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 03, 2025EPS Estimate
-1.22Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding240,398,730
10 Day Avg. Volume816,537
30 Day Avg. Volume731,368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue3.43
Enterprise Value/Gross Profit4.30
Enterprise Value/Ebitda-43.41
Forecast
1Y Price Target
$140.06Price Target Upside40.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Financial GuidanceManagement reiterated its financial guidance for 2025, which includes total revenues of €1.7-2.2B and indicates confidence in their business strategy.
Oncology DevelopmentBioNTech's BNT327 is positioned to become a future backbone in treating PD-L1 resistant tumors, highlighting its potential impact in oncology.
Patent LitigationThe patent litigation settlement with CureVac and GSK is incrementally positive, as it removes a litigation headwind and prolonged lawyer fees for BioNTech.
Bears Say
COVID-19 Vaccine RevenuesThere are potential risks with US booster adoption and evolving policy shifts, which could impact BioNTech's near-term COVID revenues.
Regulatory RisksThere is meaningful downside risk following Dr. Vinay Prasad’s exit at FDA’s Center for Biologics Evaluation and Research, especially if FDA manages to carve vaccine leadership out from the rest of CBER.
Revenue PerformanceRevenue to BioNTech in 2Q25 was significantly lower than forecasted, impacting overall financial performance.
BioNTech SE News
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $81.20 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $24.04B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2025 which is in 62 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2025. The company reported -$1.873 earnings per share for the quarter, beating the consensus estimate of -$2.672 by $0.799.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -1.22.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 240,398,730 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$1.873 in its last earnings report, beating expectations of -$2.672. Following the earnings report the stock price went up 2.506%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$140.06 (40.06% Upside)
$140.06 (40.06% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 275.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $257.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.15%
12-Months-Change
Fundamentals
Return on Equity
-1.81%
Trailing 12-Months
Asset Growth
6.57%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a biotechnology company based in Germany that focuses on the development of personalized immunotherapies for cancer and other serious diseases. The company utilizes its proprietary mRNA technology platform to create innovative therapeutics and vaccines, including its widely known COVID-19 vaccine developed in partnership with Pfizer. BioNTech operates primarily in the biopharmaceutical sector, with a strong emphasis on personalized medicine and immune-oncology.
BNTX Company Deck
BNTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with notable increases in revenue and strategic collaborations, particularly the landmark deal with BMS. However, the company reported a net loss and anticipated lower COVID-19 vaccination rates, which presented challenges.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$140.06
▲(40.06% Upside)
Technical Analysis
Ownership Overview
0.43% Insiders
4.82% Mutual Funds
13.87% Other Institutional Investors
79.92% Public Companies and
Individual Investors